Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute visual loss after ipilimumab treatment for metastatic melanoma.
Wilson MA, Guld K, Galetta S, Walsh RD, Kharlip J, Tamhankar M, McGettigan S, Schuchter LM, Fecher LA. Wilson MA, et al. Among authors: fecher la. J Immunother Cancer. 2016 Oct 18;4:66. doi: 10.1186/s40425-016-0170-9. eCollection 2016. J Immunother Cancer. 2016. PMID: 27777775 Free PMC article.
Metastatic Merkel cell carcinoma response to nivolumab.
Walocko FM, Scheier BY, Harms PW, Fecher LA, Lao CD. Walocko FM, et al. Among authors: fecher la. J Immunother Cancer. 2016 Nov 15;4:79. doi: 10.1186/s40425-016-0186-1. eCollection 2016. J Immunother Cancer. 2016. PMID: 27879975 Free PMC article.
Erratum to: Metastatic Merkel cell carcinoma response to nivolumab.
Walocko FM, Scheier BY, Harms PW, Fecher LA, Lao CD. Walocko FM, et al. Among authors: fecher la. J Immunother Cancer. 2017 Mar 6;5:27. doi: 10.1186/s40425-017-0221-x. eCollection 2017. J Immunother Cancer. 2017. PMID: 28286652 Free PMC article.
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.
Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W. Lin H, et al. Among authors: fecher la. J Clin Invest. 2018 Feb 1;128(2):805-815. doi: 10.1172/JCI96113. Epub 2018 Jan 16. J Clin Invest. 2018. PMID: 29337305 Free PMC article.
Ipilimumab induced digital vasculitis.
Padda A, Schiopu E, Sovich J, Ma V, Alva A, Fecher L. Padda A, et al. J Immunother Cancer. 2018 Feb 12;6(1):12. doi: 10.1186/s40425-018-0321-2. J Immunother Cancer. 2018. PMID: 29433584 Free PMC article.
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.
Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W. Lin H, et al. Among authors: fecher la. J Clin Invest. 2018 Apr 2;128(4):1708. doi: 10.1172/JCI120803. Epub 2018 Apr 2. J Clin Invest. 2018. PMID: 29608143 Free PMC article. No abstract available.
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.
Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL. Sullivan RJ, et al. J Immunother Cancer. 2018 May 30;6(1):44. doi: 10.1186/s40425-018-0362-6. J Immunother Cancer. 2018. PMID: 29848375 Free PMC article.
Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.
Nadeau BA, Fecher LA, Owens SR, Razumilava N. Nadeau BA, et al. Among authors: fecher la. Semin Liver Dis. 2018 Nov;38(4):366-378. doi: 10.1055/s-0038-1667358. Epub 2018 Oct 24. Semin Liver Dis. 2018. PMID: 30357774 Review.
72 results